Compare Repligen Corporation Common Stock (RGEN) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vanguard S&P 500 ETF — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while Vanguard S&P 500 ETF trades at $705.5 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 159.2× Repligen Corporation Common Stock's market cap, and Vanguard S&P 500 ETF is more actively traded (6,187,754 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vanguard S&P 500 ETF for 57 Days on average.
| RGEN | VOO | |
|---|---|---|
Market Cap | $11.31B | $1.80T |
Volume | 1,216,919 | 6,187,754 |
Sector | Health | Broad Market / Factor |
52-Week High | $194.57 | $716.17 |
52-Week Low | $102.87 | $580.93 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $11.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VOO trades at $715.14 with minimal daily movement (-0.01, -0.0%). The ETF shows strong technical momentum with bullish moving averages and neutral oscillators, while trading near pivot point resistance. Recent news highlights VOO's role in long-term wealth building through S&P 500 exposure, with discussions on dividend strategies and recession resilience.
VOO offers diversified exposure to the S&P 500 with strong institutional backing. Key risks include market volatility and interest rate sensitivity, but its low-cost structure and broad market coverage provide stability. Short interest increased 46.9% in September (Defense World, 2026-10-03), warranting monitoring of bearish sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
